MicroRNA derived from traditional Korean herbal decoction Forsythia-Astragalus extract, method of preparation thereof, and uses
MicroRNAs extracted from Forsythia-Astragalus herbal decoction effectively inhibit viral replication and treat influenza and pneumonia by targeting specific microRNAs, addressing the lack of effective pharmaceutical interventions for these infections.
Patent Information
- Application Number
- KR1020237031655
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-04-21
- Filing Date
- 2022-05-25
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-05-25
AI Technical Summary
Current treatments for influenza and novel coronavirus infections lack effective pharmaceutical interventions due to the virus's variability, and there is a lack of understanding about the specific roles of microRNAs in Korean traditional medicines.
The extraction and identification of microRNAs (QQ_159, novel_mir7, novel_mir33, etc.) from a traditional herbal decoction of Forsythia and Astragalus membranaceus, and their use in inhibiting viral replication and treating associated pneumonia.
MicroRNAs derived from Forsythia-Astragalus extract demonstrate inhibitory and therapeutic effects against influenza and pneumonia, including reducing viral load, lung inflammation, and improving survival rates in animal models.
Smart Images

Figure 112023102355285-PCT00006_ABST
Abstract
Description
Technology Field
[0001] The present invention belongs to the field of biopharmaceutical technology and, specifically, relates to microRNA derived from a traditional herbal decoction of Forsythia and Astragalus, as well as a method for manufacturing the same and its uses. Background Technology
[0002] Influenza (Flu) is an acute respiratory disease common in mammals and poultry, caused by the influenza virus. It is highly contagious and spreads rapidly, typically causing a simple respiratory infection with symptoms including cough, fever, muscle aches, chills or sweating, and other clinical signs. This discomfort can last for 2 to 8 days and generally leads to rapid disease progression. Some patients, particularly the elderly, young children, and those with other chronic conditions, are susceptible to viral or secondary pneumonia, which can even be accompanied by respiratory distress and multiple organ failure. Antiinfluenza drugs are currently the standard approach to combating influenza, and prescriptions are generally determined based on the patient's level of infection and physical condition. Although the influenza virus is one of the most deeply studied pathogens, existing control and treatment systems require continuous improvement due to the virus's extreme variability, and the development of new drugs for viral influenza is currently necessary for public and civic health.
[0003] The novel coronavirus (nCoV) is a new virus that has spread widely over the past two years. It is primarily transmitted via respiratory droplets, and recent findings indicate that the virus is also transmitted through aerosols and contact with objects. The novel coronavirus is highly contagious and spreads very rapidly; its clinical symptoms mainly include fever, fatigue, dry cough, and loss or impairment of the sense of smell. In severe cases, it may be accompanied by respiratory distress, severe pneumonia with tachycardia and hypoxemia, and may cause other complications. Since there are currently no specific treatments targeting the novel coronavirus, the virus could spread on a large scale globally. Therefore, considering the demand for pharmaceuticals for the prevention and control of infectious diseases, researching and developing new drugs specialized for nCoV is a critical means of addressing nCoV and ensuring the safety of people's lives.
[0004] MicroRNA (miRNA) is micro-endogenous non-coding RNA. Generally, miRNA-coding genes are transcribed by RNA polymerase II, which generates a primary transcript of approximately 21 nucleotides of microRNA by the RNase III endonucleases Drosha and Dicer. miRNA mediates post-transcriptional gene silencing through binding to the coding regions or 3' and 5' uncoding regions of target mRNAs that play important roles in various physiological and pathological processes, and has the potential for wide-ranging applications in the medical field.
[0005] Recently, research related to plant miRNAs has been advancing rapidly. The biological functions of plant miRNAs are primarily being studied through upregulation and downregulation strategies. Numerous studies have demonstrated that plant miRNAs play important roles in aspects such as photosynthesis, nutritional homeostasis, growth and development, hormone signaling, and stress responses. Furthermore, plant miRNAs have been shown to regulate gene expression in animals through endogenous miRNAs. While many studies report that Korean traditional medicine plays an active role in the prevention and treatment of influenza and novel coronavirus pneumonia, the specific active ingredients remain unclear. Although there have been literature reports indicating the presence of miRNAs in Korean traditional medicines, there is currently very little research regarding which stable miRNAs exist in Korean traditional decoctions and what roles these miRNAs play when they enter the bodies of animals. The problem to be solved
[0006] Considering the shortcomings of the prior art, the present invention provides a microRNA derived from a traditional herbal decoction of Forsythia and Astragalus membranaceus, a method for its preparation, and uses, as well as a functional plant microRNA or extract containing the microRNA derived from the traditional herbal decoction of Forsythia and Astragalus membranaceus. Furthermore, through experimental testing, it is demonstrated that microRNA QQ_159 derived from the Forsythia and Astragalus membranaceus extract has specific inhibitory and therapeutic effects against viral influenza and pneumonia caused by novel coronavirus infection. means of solving the problem
[0007] In order to solve the above technical problem, regarding the microRNA derived from the traditional herbal decoction Forsythia-Astragalus extract of the present invention, the microRNA is selected from novel_mir7, novel_mir33, novel_mir35, novel_mir10, novel_mir20, novel_mir5, novel_mir36, novel_mir28, novel_mir31, ppt-miR894, novel_mir32, novel_mir21, pab-miR3711, QQ_159, or bdi-miR159a-3p, wherein the nucleotide sequence of novel_mir7 is SEQ ID NO.1, the nucleotide sequence of novel_mir33 is SEQ ID NO.2, the nucleotide sequence of novel_mir35 is SEQ ID NO.3, the nucleotide sequence of novel_mir10 is SEQ ID NO.4, the nucleotide sequence of novel_mir20 is SEQ ID NO.5, and the nucleotide of novel_mir5 The sequence is SEQ ID NO.6, the nucleotide sequence of novel_mir36 is SEQ ID NO.7, the nucleotide sequence of novel_mir28 is SEQ ID NO.8, the nucleotide sequence of novel_mir31 is SEQ ID NO.9, the nucleotide sequence of ppt-miR894 is SEQ ID NO.10, the nucleotide sequence of novel_mir32 is SEQ ID NO.11, the nucleotide sequence of novel_mir21 is SEQ ID NO.12, the nucleotide sequence of pab-miR3711 is SEQ ID NO.13, the nucleotide sequence of QQ_159 is SEQ ID NO.14, and the nucleotide of bdi-miR159a-3p is SEQ ID NO.15.
[0008] The above microRNA is one of the following: artificially synthesized QQ_159, plant QQ_159, and QQ_159 in a precursor form or a mature form.
[0009] A method for producing microRNA derived from traditional herbal decoction Forsythia-Astragalus extract includes the following steps.
[0010] Step 1) Divide 300 ml of each traditional herbal decoction Forsythia-Astragalus extract into 50 ml enzyme-removing centrifuge tubes, centrifuge at 2000 rpm to remove impurities, draw 10 ml of the supernatant from each tube and place it on ice, add 30 ml of Trisol at a ratio of 3 times the decoction volume, shake vigorously and uniformly to mix, and leave at room temperature for 10 minutes, then add 6 ml of chloroform, shake vigorously and uniformly to mix, and let stand for 10 minutes, Step 2) Centrifuge at 10,000 g and 4 ℃ for 10 minutes and collect the supernatant, Step 3) Add an equal volume of isopropanol to the mixture and precipitate at -20 ℃ for 1 hour, then centrifuge at 12,000 g for 15 minutes to precipitate, Step 4) Carefully remove the supernatant, add 5 ml of 75% ethanol to wash the precipitate, and Step 5) Centrifuge at 12,000 g at 4°C for 5 minutes to wash the precipitate, and after centrifugation, carefully remove the ethanol, leave the precipitate, dry the precipitate, add 200 μL of 65°C DEPC-treated water to dissolve the precipitate, and determine the RNA concentration, Step 6) the miRNA is purified by a commercial miRNA isolation kit (100 μg of RNA passes through each column) and dissolved in each tube with 60 μL of DEPC-treated water, Step 7) determine the miRNA concentration, freeze-dry for 8 hours, and store at -80°C.
[0011] A method for manufacturing a drug to inhibit the replication of the influenza virus through microRNA derived from a traditional herbal decoction of Forsythia and Astragalus.
[0012] Method for preparing a drug for treating influenza virus using microRNA derived from traditional herbal decoction Forsythia-Astragalus extract.
[0013] A method for manufacturing a drug in which the above-mentioned influenza is Victoria influenza B or H5N1 avian influenza.
[0014] Method for manufacturing a drug to inhibit SARS-CoV-2 virus replication through microRNA derived from traditional herbal decoction Forsythia-Astragalus extract.
[0015] A method for preparing a drug for treating viral pneumonia caused by SARS-CoV-2 virus using microRNA derived from a traditional herbal decoction of Forsythia-Astragalus extract.
[0016] A pharmaceutical composition for inhibiting influenza virus replication and / or treating influenza comprising microRNAs QQ_159 and a pharmaceutically acceptable carrier thereof.
[0017] A pharmaceutical composition for inhibiting the replication of SARS-CoV-2 virus and / or treating viral pneumonia caused by SARS-CoV-2 virus, comprising microRNAs QQ_159 and a pharmaceutically acceptable carrier thereof. Effects of the invention
[0018] The present invention provides an experimental method for extracting microRNA from traditional herbal medicine liquids, through which 15 types of microRNAs stably present in a traditional herbal decoction of Forsythia and Astragalus membranaceus were extracted and identified for the first time. MicroRNA QQ_159 was proven to have specific inhibitory and therapeutic effects against viral influenza and pneumonia caused by novel coronavirus infection. The present invention not only provides natural antiviral active ingredients of Korean medicine but also provides a nucleic acid drug capable of clinically treating influenza or pneumonia caused by novel coronavirus infection. Brief explanation of the drawing
[0019] Figure 1 shows the inhibitory effect of microRNA QQ_159, tested by real-time PCR in Example 2, on the influenza B virus load. Figure 2 shows the effect of microRNA QQ_159 on body weight of mice infected with the avian influenza H5N1 virus in Example 3. Figure 3 shows the effect of microRNA QQ_159 on the survival rate of mice infected with avian influenza H5N1 virus in Example 3. Figure 4 shows the inhibitory effect of microRNA QQ_159 on lung inflammation in mice infected with avian influenza H5N1 through the HE staining test in Example 3. Figure 5 shows the inhibitory effect of microRNA QQ_159 on the lung virus load of mice infected with avian influenza H5N1 on day 3 (A) and day 5 (B) as examined by real-time PCR in Example 3. Figure 6 shows the inhibitory effect of microRNA QQ_159 on lung inflammation in mice infected with SARS-CoV-2 virus through HE staining detection in Example 4. Specific details for implementing the invention
[0020] To clarify the technical problems, technical solutions, and advantages of the present invention, the following detailed description and specific embodiments are described with reference to the attached drawings.
[0021] Example 1: MicroRNA extraction from traditional herbal decoction Forsythia-Astragalus extract
[0022] (1) Divide 300 ml of traditional herbal decoction of Forsythia-Astragalus extract (Lonicerae Japonicae Flos, Forsythiae Fructus, Scutellariae Radix, Artemisiae Annuae Herba, raw Astragalus Radix, roasted Atractylodis Macrocephalae Rhizoma, Agastache rugosa, Saposhnikoviae Radix, Ophiopogon japonicus, Glycyrrhiza uralensis) into 50 ml enzyme removal centrifuge tubes and centrifuge at 2000 rpm to remove impurities. Draw 10 ml of the supernatant from each tube and place it on ice. Add 30 ml of Trisol at a ratio of 3 times the amount of decoction, shake vigorously and evenly to mix, and leave at room temperature for 10 minutes, then add 6 ml of chloroform, shake vigorously and evenly to mix, and let stand for 10 minutes.
[0023] (2) Centrifuge at 10,000 g, 4 ℃ for 10 minutes and collect the supernatant.
[0024] (3) Add an equal volume of isopropanol to the mixture and precipitate for 1 hour (-20℃), then centrifuge at 12000 g for 15 minutes to precipitate.
[0025] (4) Carefully remove the supernatant and wash the precipitate by adding 5 mL of 75% ethanol, then centrifuge at 12,000 g at 4°C for 5 minutes.
[0026] (5) After centrifugation, carefully remove the ethanol and leave the precipitate. After drying the precipitate, add 200 μL of 65°C DEPC-treated water to dissolve the precipitate and determine the RNA concentration.
[0027] (6) miRNA is purified by a commercial miRNA isolation kit (100 μg of RNA passes through each column) and dissolved in 60 μL of DEPC-treated water in each tube.
[0028] (7) Determine the concentration of miRNA, freeze-dry for 8 hours, and store at -80℃.
[0029] (8) The base sequence of miRNA was analyzed using the BGISEQ-500 technique, and the results are shown in Table 1 below.
[0030] Table 1 is a list of microRNA sequences derived from traditional Korean herbal decoction Forsythia-Astragalus extract.
[0031] miRNA id SEQ ID Sequence(5'-3') novel_mir7 1 CCAGCACUAAUGCACCGGAUCCCAUCAG novel_mir33 2 UGGGAAGUCCUCGUGUUGUACCCCU novel_mir35 3 GCCUUCGAUGUCGGCUCUUCCUAUCAUU novel_mir10 4 UCGUCCAGCGGUUAGGAUAUCUGGCUUUC novel_mir20 5 GCGGAUCUUGGUGGUAGUAGCAAA novel_mir5 6 CUCGGGAAAAGGAUUGGCUCUGAGGGCUGG novel_mir36 7 ACACAUGCAAGUCGAACGUUGUUUU novel_mir28 8 GUGUGCACCGGUCGUCUCGUCCCUUCUG novel_mir31 9 UCUGGGUGGUGUAGUUGGUUAUCA ppt-miR894 10 CGUUUCACGUCGGGUUCACC novel_mir32 11 GUGGUUAGGACAUCGUCUUUUCA novel_mir21 12 GUCUGUAGUUCGAUCCUGCAUGGGGG pab-miR3711 13 UGGCGCUAGAAGGAGGGCCU QQ_159 14 UUUGGAUUGAAGGGAGCUCUA bdi-miR159a-3p 15 CUUGGAUUGAAGGGAGCUCU
[0032] Example 2: Determination of the effect of QQ_159 on influenza B virus load in MDCK (Madin Darby dog kidney) cells
[0033] (1) MDCK cells are cultured in a 24-well culture plate.
[0034] (2) 10 nM, 50 nM, or 100 nM QQ_159a are each transfected into MDCK cells by the commercial transfection reagent riboFECT™ CP, while the same concentration of nonsense sequence is transfected into MDCK cells as a control.
[0035] (3) The above cell is a cell infected with Victoria B influenza virus.
[0036] (4) After infecting with the virus for 24 hours, the supernatant is collected, centrifuged, and the cells are merged to extract RNA, and then the viral load is detected by real-time PCR.
[0037] The results are as shown in Figure 1, and compared to the control group, 100 nM QQ_159 can significantly inhibit the viral load of Victoria B influenza virus in MDCK cells.
[0038] Example 3: Measurement of the therapeutic effect of QQ_159 on rats infected with H5N1 subtype avian influenza virus
[0039] (1) The drug was administered intraperitoneally to 6-week-old female BALB / C rats 2 hours after being infected with the H5N1 subtype avian virus, and the animal group and drug dosage are as shown in Table 2 below.
[0040] Table 2 QQ_159 Animal Experiment Group and Treatment for Animal-borne Avian Influenza Resistance H5N1
[0041] Groups Dosages of virus attack Administration dosages Administration mode Administration times Number of mice Group1 M-QQ_159 30 LD50 / 50μL 120 pmol / per mouse / day0.1 mL Intraperitoneal injection (DEPC-treated waterdilution QQ_159) 5 16 Group2 H-QQ_159 30 LD50 / 50μL 360 pmol / per mouse / day0.1 mL Intraperitoneal injection (DEPC-treated waterdilution QQ_159) 5 16 Group3 Mixed RNAGroup 30 LD50 / 50μL 270 μg / per mouse / day0.1 mL Intraperitoneal injection (DEPC-treated waterdilution mixed RNA) 5 16 Group4 Infection Control Group 30 LD50 / 50μL DEPC-treated water0.1 mL Intraperitoneal injection (DEPC-treated water) 5 16 Group5 Normal control group DEPC-treated water 50μL DEPC-treated water0.1 mL Intraperitoneal injection (DEPC-treated water) 5 16
[0042] In Table 2, Mixed RNA is Mixed RNA collectively extracted from the traditional herbal decoction Forsythia-Astragalus extract.
[0043] (2) Continue administration for 5 days and observe and record changes in body weight daily (euthanize if body weight decreases by more than 30%).
[0044] (3) Lung tissue is collected on the 3rd and 5th days after viral infection, respectively, and the inflammatory state of the lung tissue is detected by HE staining.
[0045] (4) The viral load in lung tissue is detected by real-time PCR.
[0046] (5) Raise the animals for 10 days and observe the survival rate.
[0047] As a result, as shown in Fig. 2, regarding changes in body weight, on the 7th day after viral infection, the changes in body weight of the medium concentration QQ_159 (120 pmol / per mouse / day, M-QQ_159), high concentration QQ_159 (360 pmol / per mouse / day, H-QQ_159), and mixed RNA groups (D8 shown in Fig. 2) enter a stable phase, but the infected control group still shows a decreasing trend, and the rate of change in body weight of the high concentration QQ_159 group is slightly higher than that of the mixed RNA group and the medium concentration QQ_159 group. As shown in Fig. 3, regarding survival rates, the survival rates of the medium concentration QQ_159 group and the mixed RNA group are 70%, the survival rate of the high concentration QQ_159 group is 50%, and the survival rate of the infected group is only 30%. As shown in Figure 4, the HE results show that lung inflammation is significantly reduced in mice of the mixed RNA group and the medium concentration QQ_159 group, and that the medium concentration QQ_159 group exhibits a superior inhibitory effect compared to the infected control group. As shown in Figure 5a, the medium concentration QQ_159 group, the high concentration QQ_159 group, and the mixed RNA group all have an inhibitory effect on viral replication on day 3 after infection; as shown in Figure 5b, the inhibitory effect on viral replication in the medium concentration QQ_159 group significantly decreased on day 5 after infection, whereas the high concentration QQ_159 group and the mixed RNA group still show a superior inhibitory effect on viral replication.
[0048] Experimental results showed that artificially synthesized QQ_159 and mixed RNA extracted from a traditional herbal decoction of Forsythia and Astragalus membranaceus exhibited a certain therapeutic effect against the H5N1 avian influenza virus. The H5N1 avian influenza virus is characterized by delaying body weight loss, reducing mortality, and decreasing lung inflammation.
[0049] Example 4: Study on the Inhibitory Effect of QQ_159 on Pneumonia Caused by SARS-CoV-2 Virus
[0050] (1) 6 to 8 weeks old hACE2 rats are infected with SARS-CoV-2 in the form of 105TCID50 / ml via the nose.
[0051] (2) Mice are administered intraperitoneal (IP) injection for 5 days, 2 hours after infection on the first day, and the experimental test group and dosage are as shown in Table 3 below.
[0052] Table 3 SARS-CoV-2 Infection Experiment in hACE2 Transgenic Mice
[0053] Group Administration dosages Administration volume Administration mode Time of virus attack Times 1 60 pmol / per mouse / day 100 μL / per mouse ip Administration after infection of 2h 5 2 120 pmol / per mouse / day 100 μL / per mouse ip Administration after infection of 2h 5 3 180 pmol / per mouse / day 100 μL / per mouse ip Administration after infection of 2h 5 Control Group - 100 μL / per mouse ip Virus attack at day 0 5
[0054] (3) Observe weight and symptoms on days 0, 1, 2, 3, 4, and 5.
[0055] (4) On the 5th day after infection, sacrifice the rat and collect lung tissue.
[0056] (5) Detect lung pathology with HE staining.
[0057] As shown in Figure 6, an injection dose of 120 pmol / day of QQ_159 per rat showed a certain inhibitory effect on lung tissue inflammation in hACE2 transgenic rats infected with SARS-CoV-2, which indicates that QQ_159 has a certain inhibitory effect on rat pneumonia caused by SARS-CoV-2 infection.
[0058] The above are merely preferred embodiments of the present disclosure, and it should be noted that for those skilled in the art, numerous modifications and adaptations may be made without departing from the principles of the present disclosure, and such modifications and adaptations should be considered to be within the scope of protection of the present disclosure.
[0059] List of nucleotide and amino acid sequences of the specification
[0060] Sequence list
[0061] <110> Nantong University
[0062] <120> MicroRNAs derived from Forsythiae Fructus-Astragalus Radix compound traditional Chinese medicine decoction as well as preparation method and use thereof {MICRORNAS FROM FORSYTHIAE FRUCTUS-ASTRAGALI RADIX COMPOUND TRADITIONAL CHINESE MEDICINE DECOCTION AS WELL AS PREPARATION METHOD AND USE THEREOF} Real-time braking distance measuring device and method of truck
[0063] <160> 15
[0064] <170> SIPOSequenceListing 1.0
[0065] <210> 1
[0066] <211> 28
[0067] <212> RNA
[0068] <213> Artificial Sequence
[0069] <400> 1
[0070] ccagcacuaa ugcaccggau cccaucag 28
[0071] <210> 2
[0072] <211> 25
[0073] <212> RNA
[0074] <213> Artificial Sequence
[0075] <400> 2
[0076] ugggaagucc ucguguugua ccccu 25
[0077] <210> 3
[0078] <211> 28
[0079] <212> RNA
[0080] <213> Artificial Sequence
[0081] <400> 3
[0082] gccuucgaug ucggcucuuc cuaucauu 28
[0083] <210> 4
[0084] <211> 29
[0085] <212> RNA
[0086] <213> Artificial Sequence
[0087] <400> 5
[0088] gcggaucuug gugguaguag caaa 24
[0089] <210> 6
[0090] <211> 30
[0091] <212> RNA
[0092] <213> Artificial Sequence
[0093] <400> 6
[0094] cucgggaaaa ggauuggcuc ugagggcugg 30
[0095] <210> 7
[0096] <211> 25
[0097] <212> RNA
[0098] <213> Artificial Sequence
[0099] <400> 7
[0100] acacaugcaa gucgaacguu guuuu 25
[0101] <210> 8
[0102] <211> 28
[0103] <212> RNA
[0104] <213> Artificial Sequence
[0105] <400> 8
[0106] gugugcaccg gucgucucgu cccuucug 28
[0107] <210> 9
[0108] <211> 24
[0109] <212> RNA
[0110] <213> Artificial Sequence
[0111] <400> 9
[0112] ucuggguggu guaguugguu auca 24
[0113] <210> 10
[0114] <211> 20
[0115] <212> RNA
[0116] <213> Artificial Sequence
[0117] <400> 10
[0118] cguuucacgu cggguucacc 20
[0119] <210> 11
[0120] <211> 23
[0121] <212> RNA
[0122] <213> Artificial Sequence
[0123] <400> 11
[0124] gugguuagga caucgucuuu uca 23
[0125] <210> 12
[0126] <211> 26
[0127] <212> RNA
[0128] <213> Artificial Sequence
[0129] <400> 12
[0130] gucuguaguu cgauccugca uggggg 26
[0131] <210> 13
[0132] <211> 20
[0133] <212> RNA
[0134] <213> Artificial Sequence
[0135] <400> 13
[0136] uggcgcuaga aggagggccu 20
[0137] <210> 14
[0138] <211> 21
[0139] <212> RNA
[0140] <213> Artificial Sequence
[0141] <400> 14
[0142] uuuggauuga agggagcucu a 21
[0143] <210> 15
[0144] <211> 20
[0145] <212> RNA
[0146] <213> Artificial Sequence
[0147] <400> 15
[0148] cuuggauuga agggagcucu 20
Claims
Claim 1 A pharmaceutical composition for treating viral influenza comprising a microRNA derived from a traditional herbal decoction of Forsythia-Astragalus extract, wherein the microRNA is QQ_159, the nucleotide sequence of QQ_159 is as described in SEQ ID NO. 14, and the influenza comprises Victoria influenza B or H5N1 avian influenza. Claim 2 A pharmaceutical composition for treating viral pneumonia caused by SARS-CoV-2 virus, wherein the microRNA derived from a traditional herbal decoction Forsythia-Astragalus extract is QQ_159, and the nucleotide sequence of QQ_159 is as described in SEQ ID NO.
14. Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 delete
Citation Information
Patent Citations
Application of soybean RNA extract in preparation of medicine for preventing and treating enteritis
CN111249299A
Traditional Chinese medicine compound preparation for treating viral pneumonia
CN113332377A
Application of bupleurum tenuifolium extract in treatment of viral pneumonia
CN112569332A
